Partner Content Partner Content STORM Therapeutics Announces Publication in Nature on RNA Ep... RNA Therapeutics
News PMV cues up filing for first p53-directed cancer therapy PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
